生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展

doi:10.35541/cjd.20191176

Abstract

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic recurrent inflammatory disease, and biological agents targeting cytokines and their receptors involved in its pathogenesis have become an increasingly important option for its treatment in recent years. With the successive appearance of biological agents such as secukinumab and ustekinumab on the market in China, the use of biologics will become increasingly common in the treatment of psoriasis. This review summarizes the efficacy of different biological agents and individualized drug selection in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, with a view to providing a reference for physicians in clinical practice.

Key words: Psoriasis, Biological agents, Tumor necrosis factor?alpha, Interleukin?17, Interleukins, Treatment outcome, Moderate to severe plaque psoriasis

Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis[J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75.doi:10.35541/cjd.20191176

References ［29］

［1］	Gisondi P, Geat D, Pizzolato M, et al. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis［J］. Curr Opin Pharmacol, 2019,46:90⁃99. doi: 10.1016/j.coph.2019.05.007.
［2］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［3］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics ［J］. J Am Acad Dermatol, 2019, 80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［4］	Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2017,376（16）:1551⁃1560. doi: 10.1056/NEJMoa1607017.
［5］	Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate⁃to⁃severe plaque psoriasis up to 1 year: results from the CLEAR study［J］. J Am Acad Dermatol, 2017,76（1）:60⁃69.e9. doi: 10.1016/j.jaad.2016.08.008.
［6］	Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate⁃to⁃severe psoriasis （UNCOVER⁃2 and UNCOVER⁃3）: results from two phase 3 randomised trials［J］. Lancet, 2015,386（9993）:541⁃551. doi: 10.1016/S0140⁃6736（15）60125⁃8.
［7］	Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials［J］. Br J Dermatol, 2019,180（2）:306⁃314. doi: 10.1111/bjd.17318.
［8］	Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12⁃week randomized, double⁃blinded, placebo⁃controlled phase 2b trial［J］. J Am Acad Dermatol, 2018,79（2）:277⁃286.e10. doi: 10.1016/j.jaad.2018.03.037.
［9］	Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate⁃to⁃severe plaque psoriasis （UltIMMa⁃1 and UltIMMa⁃2）: results from two double⁃blind, randomised, placebo⁃controlled and ustekinumab⁃controlled phase 3 trials［J］. Lancet, 2018,392（10148）:650⁃661. doi: 10.1016/S0140⁃6736（18）31713⁃6.
［10］	Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis （reSURFACE 1 and reSURFACE 2）: results from two randomised controlled, phase 3 trials［J］. Lancet, 2017,390（10091）:276⁃288. doi: 10.1016/S0140⁃6736（17）31279⁃5.
［11］	Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab （LY3074828） in the treatment of moderate⁃to⁃severe plaque psoriasis: results from a randomized phase II study［J］. Br J Dermatol, 2019,181（1）:88⁃95. doi: 10.1111/bjd.17628.
［12］	Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate⁃to⁃severe plaque psoriasis［J］. Br J Dermatol, 2018,178（2）:509⁃519. doi: 10.1111/bjd.16102.
［13］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039.
［14］	Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management［J］. J Am Acad Dermatol, 2017,76（3）:393⁃403. doi: 10.1016/j.jaad.2016.07.065.
［15］	Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2018,29（1）:13⁃18. doi: 10.1080/09546634. 2017.1329511.
［16］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］.中华皮肤科杂志,2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892.
［17］	Amin M, No DJ, Egeberg A, et al. Choosing first⁃line biologic treatment for moderate⁃to⁃severe psoriasis: what does the evidence say?［J］. Am J Clin Dermatol, 2018,19（1）:1⁃13. doi: 10.1007/s40257⁃017⁃0328⁃3.
［18］	Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196.
［19］	Torgutalp M, Poddubnyy D. Emerging treatment options for spondyloarthritis ［J］. Best Pract Res Clin Rheumatol, 2018, 32（3）:472⁃484. doi: 10.1016/j.berh.2019.01.014.
［20］	Raychaudhuri SP, Wilken R, Sukhov AC, et al. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies［J］. J Autoimmun, 2017,76:21⁃37. doi: 10.1016/j.jaut.2016.10.009.
［21］	Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin⁃17A specific monoclonal antibody, for the treatment of biologic⁃naive patients with active psoriatic arthritis: results from the 24⁃week randomised, double⁃blind, placebo⁃controlled and active （adalimumab）⁃controlled period of the phase III trial SPIRIT⁃P1［J］. Ann Rheum Dis, 2017,76（1）:79⁃87. doi: 10.1136/annrheumdis⁃2016⁃209709.
［22］	Van den Bosch F, Coates L. Clinical management of psoriatic arthritis［J］. Lancet, 2018,391（10136）:2285⁃2294. doi: 10.1016/S0140⁃6736（18）30949⁃8.
［23］	McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double⁃blind, placebo⁃controlled PSUMMIT 1 trial［J］. Lancet, 2013,382（9894）:780⁃789. doi: 10.1016/S0140⁃6736（13）60594⁃2.
［24］	Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double⁃blind, phase III FUTURE 5 study［J］. Ann Rheum Dis, 2018,77（6）:890⁃897. doi: 10.1136/annrheumdis⁃2017⁃212687.
［25］	Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti⁃IL17RA monoclonal antibody, in psoriatic arthritis［J］. N Engl J Med, 2014,370（24）:2295⁃2306. doi: 10.1056/NEJMoa1315231.
［26］	Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
［27］	刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］.中华皮肤科杂志,2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757.
［28］	朱晨雨, 孙秋宁, 舒畅, 等. 英夫利西单抗治疗重度银屑病17例临床观察［J］.中华皮肤科杂志,2016,49（4）:294⁃295. doi: 10.3760/cma.j.issn.0412⁃4030.2016.04.021.
［29］	Huang H, Cai ML, Hong XJ, et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi: 10.1684/ejd.2020.3878.

[1]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[2]	Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865.
[3]	Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394.
[4]	Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448.
[5]	Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190.
[6]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.
[7]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.
[8]	Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2024, 57(2): 161-165.
[9]	Zhang Qian, Zhang Jin′e, Guo Sen, Song Pu, Gao Lin, Li Chunying. Comparison of the efficacy of fractional CO2 laser combined with topical delivery of fluorouracil versus compound betamethasone injections in the treatment of vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2024, 57(1): 34-38.
[10]	Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang. Janus kinase inhibitors for the treatment of five children with severe alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852.
[11]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[12]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[13]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[14]	Wang Junxia, Guo Weinan, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Efficacy of autologous fat grafting in the treatment of 40 cases of stable linear scleroderma: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(8): 762-765.
[15]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.

Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［29］

Related Articles 15

Metrics

Comments

Recommended 10